Kidney Cancer
Prostate Cancer
EAU Edu Platform on Bladder Cancer
Home
Articles
Article of the Month
Editorial
Videos
Webcasts
Education
Curriculum NMIBC
E-courses
Webinars
ESOU Online
Clinical problems
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorial
Videos
Webcasts
Education
Terug
Curriculum NMIBC
E-courses
Webinars
ESOU Online
Clinical problems
Guidelines
Events
Upcoming event
Masterclass on Non-muscle-invasive bladder cancer
Home
/
Videos
Back
EMUC26
EMUC24
EAU24
EAU23
ASCO GU23
EMUC2022
ESMO2022
EAU22
ASCO GU22
EMUC21
EAU 21
ESOU 21
ASCO GU21
EAU20
ESOU Online
ASCO19
EAU19
GU19
EMUC 2018
Surgery
EMUC 2014
ESMO 2014
ERUS 2014
Filter
Tags
(neo)adjuvant therapy
,
5-α reductase inhibitors
,
Androgen antagonists
,
Article of the Month
,
ASCO GU2026
,
ASCO GU21
,
ASCO GU22
,
ASCO2026
,
ASCO21
,
AUA21
,
BCG
,
BCG therapy
,
BCG-unresponsive disease
,
Bladder cancer
,
Bladder neoplasms
,
Bladder-sparing therapy
,
Bladder-sparing trimodality
,
Chemoradiotherapy
,
cisplatin
,
Clinical pathways
,
Clinical staging
,
Collaborative care
,
Comorbidity
,
Cystectomy
,
disitamab vedotin
,
Early recurrence patterns
,
EAU21
,
EAU22
,
EAU26
,
EMUC21
,
EMUC22
,
ENERGIZE trial
,
enfortumab vedotin
,
EORTC
,
ERBB2
,
ERCC2
,
ESMO 2026
,
ESMO21
,
ESOU21
,
ESOU22
,
EV-303
,
EV-304
,
FAP PET/MRI
,
FAP-targeted imaging
,
FDG PET
,
FDG PET/CT
,
FinnBladder 9
,
gemcitabine
,
Gene expression analysis
,
Guidelines
,
Hematuria
,
HER2
,
High-risk NMIBC
,
Highlight of the Month
,
Immune checkpoint
,
Immune checkpoint blockade
,
Immunoregulation
,
Immunotherapy
,
Intravesical therapy
,
KEYNOTE-866
,
Laparoscopic radical cystectomy
,
Masterclass
,
Masterclass on MIBC
,
Masterclass on NMIBC
,
Meta-analysis
,
Metastatic urothelial cancer
,
MIBC
,
Microscopic haematuria
,
Molecular subtypes
,
Multiparametric MRI
,
muscle-invasive bladder cancer
,
Nadofaragene firadenovec
,
Nectin-4 PET
,
Neoadjuvant
,
Neoadjuvant chemotherapy
,
neoadjuvant enfortumab vedotin
,
Neoplasm recurrence
,
Nephroureterectomy
,
NIBC
,
nivolumab
,
NMIBC
,
Non-visible haematuria
,
Non–muscle-invasive bladder cancer
,
Nuclear matrix protein 22
,
Oncologic outcomes
,
Open radical cystectomy
,
Optical coherence
,
pathologic complete response
,
PD-1 inhibitor
,
PD-L1
,
Pembrolizumab
,
perioperative
,
perioperative checkpoint inhibition
,
Perioperative durvalumab
,
perioperative pembrolizumab
,
PET
,
PLND
,
Postoperative complications
,
POUT trial
,
Prevention & control
,
Quality of life
,
Radical cystectomy
,
Radio-chemotherapy
,
Randomized controlled trial
,
RARC
,
RAZOR Trial
,
Recurrence
,
Robotic
,
Robotic prostatectomy
,
Robotic radical cystectomy
,
Robotic surgery
,
segmental ureterectomy
,
Summer reads
,
Surgical video
,
Surgical videos
,
Systematic review
,
targeted therapy
,
tislelizumab
,
Tomography
,
Transitional cell
,
Transitional cell carcinoma
,
Tregs
,
tremelimumab
,
upper tract urothelial carcinoma
,
Urinary bladder neoplasms
,
Urinary diversion
,
Urological surgery
,
UROonco24
,
UROonco25
,
Urothelial cancer
,
Urothelium
,
UROwebinar
,
UTUC
,
UTUC stagging
,
VOLGA
,
VOLGA trial
,
Webinar
,
WUTSUP-02
Show all
DUTRENEO Trial
Watch now
IDENTIFY study
Watch now
Focus on Bladder Immunotherapy and the Young Patient
Watch now
EAU19 Oncology Best Poster about implications for anti-FGFR3 bladder cancer treatment
Watch now
Focus on Bladder Genetics
Watch now
Discussing with Prof. Axel Merseburger about the primary results from the SAUL study
Watch now
Interview with Prof. Nguyen
Watch now
Interview with Prof. Kamat
Watch now
Interview with Dr. Balar
Watch now
EMUC18: Interview with Prof. Marek Babjuk
Watch now
EMUC18: POUT trial
Watch now
Improving outcome of patients with muscle invasive bladder cancer
Watch now
Previous
Next
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
I agree
Read More